Non-Insulin Therapies For Diabetes Global Market Report 2025

Description

Non-insulin therapies for diabetes are treatments and medications designed to manage blood sugar levels in diabetic patients without the need for insulin injections. These therapies play a crucial role in regulating blood glucose levels for patients who either do not require insulin or prefer alternative methods of treatment.

The primary classes of drugs in the non-insulin therapies for diabetes market include biguanides, sulfonylureas, thiazolidinediones, alpha-glucosidase inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) analogs, and sodium-glucose co-transporter-2 (SGLT2) inhibitors. Biguanides, for instance, are oral hypoglycemic agents that target type 2 diabetes by reducing liver glucose production and improving insulin sensitivity. These medications can be administered orally or intramuscularly and are distributed through various channels such as retail pharmacies, hospital pharmacies, and online pharmacies. They are utilized for purposes such as monitoring, diagnosis, treatment, and more.

The non-insulin therapies for diabetes market research report is one of a series of new reports from The Business Research Company that provides non-insulin therapies for diabetes market statistics, including the non-insulin therapies for diabetes industry global market size, regional shares, competitors with non-insulin therapies for diabetes market share, detailed non-insulin therapies for diabetes market segments, market trends, and opportunities, and any further data you may need to thrive in the non-insulin therapies for diabetes industry. These non-insulin therapies for diabetes market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The non-insulin therapies for diabetes market size has grown strongly in recent years. It will grow from $19.98 billion in 2024 to $21.41 billion in 2025 at a compound annual growth rate (CAGR) of 7.1%. The growth in the historic period can be attributed to increasing diabetes prevalence, increasing awareness of diabetes management, rise in healthcare expenditure, shift in lifestyle changes leading to higher incidence rates, surge in diagnosis, increasing government initiatives for diabetes care, and increasing investment in pharmaceutical R&D.

The non-insulin therapies for diabetes market size is expected to see strong growth in the next few years. It will grow to $27.9 billion in 2029 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to rising diabetes prevalence, increasing awareness of diabetes management, growing adoption of combination therapies, expanding geriatric population, increasing healthcare expenditure, expansion of telemedicine, and growing preference for oral medications. Major trends in the forecast period include advancements in oral and injectable medications, advancements in drug delivery systems, advancements in oral peptide delivery, adoption of telemedicine and digital health solutions, and advancements in combination therapies.

The rising prevalence of diabetes is anticipated to drive the growth of the non-insulin therapies market for diabetes in the future. Diabetes is a chronic condition marked by elevated blood glucose (sugar) levels, occurring when the body cannot produce adequate insulin or properly utilize the insulin it produces. The increase in diabetes cases is linked to sedentary lifestyles, unhealthy diets, genetic predisposition, aging populations, obesity, ethnicity, lack of awareness, limited healthcare access, and environmental factors. Non-insulin therapies for diabetes aid in managing the condition by enhancing insulin sensitivity, lowering glucose production in the liver, boosting glucose uptake in muscle cells, and improving overall glycemic control. For example, in April 2023, a report from The British Diabetic Association, a UK-based diabetes charity, indicated that 4.3 million people in the UK had been diagnosed with diabetes. Registration data for 2021-22 reflected a rise of 148,951 cases compared to 2020-21, with over 2.4 million individuals at high risk of developing type 2 diabetes. Consequently, the growing prevalence of diabetes is driving the expansion of the non-insulin therapies market for diabetes.

Leading companies in the non-insulin therapies market are focusing on personalized diabetes management systems to improve patient outcomes through real-time monitoring, data analysis, and customized treatment plans. Personalized systems adapt treatment strategies and monitoring based on individual patient needs, leveraging real-time data and analytics to optimize care. For instance, Eli Lilly and Company introduced the Tempo personalized diabetes management platform in November 2022. This platform integrates the Tempo Smart Button, TempoSmart app, and prefilled insulin pen (Tempo Pen) to deliver tailored guidance for adults with diabetes. The technology assists both type 1 and type 2 diabetes patients and their healthcare providers in making informed, data-driven treatment decisions using Lilly insulins.

In August 2023, Eli Lilly and Company acquired Sigilon Therapeutics Inc. for $309.6 million, enhancing its research and development efforts in encapsulated cell therapies such as SIG-002 for type 1 diabetes treatment. This acquisition reflects Lilly's commitment to advancing solutions that alleviate the continuous disease management burden for individuals with type 1 diabetes. Sigilon Therapeutics Inc. is a biopharmaceutical company specializing in encapsulated cell therapies for type 1 diabetes treatment.

Major companies operating in the non-insulin therapies for diabetes market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Sanofi, The Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GSK plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Les Servier Laboratories, Sumitomo Dainippon Pharma Co. Ltd., Jiangsu Hansoh Pharmaceutical Group Co. Ltd., Uni-Bio Science Group Ltd., Intarcia Therapeutics, Janssen Pharmaceuticals, Boan Biotech, SatRx LLC

North America was the largest region in the non-insulin therapies for diabetes market in 2024. The regions covered in the non-insulin therapies for diabetes market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the non-insulin therapies for diabetes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The non-insulin therapies for diabetes market consist of sales of glucose meters, continuous glucose monitors (CGMs), insulin pumps, smart insulin pens, oral medications such as metformin and sulfonylureas, and injectable medications such as glp-1 receptor agonists. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Non-Insulin Therapies For Diabetes Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on non-insulin therapies for diabetes market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for non-insulin therapies for diabetes ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The non-insulin therapies for diabetes market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Drug Class: Biguanides; Sulfonylureas; Thiazolidinedione's; Alpha-Glucosidase Inhibitors; Dipeptidyl peptidase-4 (DPP-4) Inhibitors; Glucagon-like peptide-1 (GLP-1) Analogs; Sodium-glucose co-transporter-2 (SGLT2) Inhibitors
2) By Route Of Administration: Oral; Intramuscular
3) By Distribution Channel: Retail Pharmacy; Hospital Pharmacy; Online Pharmacy
4) By Application: Monitoring; Diagnosis; Treatment; Other Applications
Subsegments:
1) By Biguanides: Metformin; Combination Of Metformin With Other Drugs
2) By Sulfonylureas: Glimepiride; Glipizide; Glyburide
3) By Thiazolidinediones: Pioglitazone; Rosiglitazone
4) By Alpha-Glucosidase Inhibitors: Acarbose; Miglitol
5) By Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: Sitagliptin; Saxagliptin; Linagliptin; Alogliptin
6) By Glucagon-Like Peptide-1 (GLP-1) Analogs: Exenatide; Liraglutide; Dulaglutide; Semaglutide
7) By Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors: Canagliflozin; Dapagliflozin; Empagliflozin
Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche AG; Merck & Co. Inc.; Sanofi; The Bristol-Myers Squibb Company
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r30794

1. Executive Summary

2. Non-Insulin Therapies For Diabetes Market Characteristics

3. Non-Insulin Therapies For Diabetes Market Trends And Strategies

4. Non-Insulin Therapies For Diabetes Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Non-Insulin Therapies For Diabetes Growth Analysis And Strategic Analysis Framework

5.1. Global Non-Insulin Therapies For Diabetes PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Non-Insulin Therapies For Diabetes Market Growth Rate Analysis
5.4. Global Non-Insulin Therapies For Diabetes Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Non-Insulin Therapies For Diabetes Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Non-Insulin Therapies For Diabetes Total Addressable Market (TAM)

6. Non-Insulin Therapies For Diabetes Market Segmentation

6.1. Global Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Biguanides
Sulfonylureas
Thiazolidinedione's
Alpha-Glucosidase Inhibitors
Dipeptidyl peptidase-4 (DPP-4) Inhibitors
Glucagon-like peptide-1 (GLP-1) Analogs
Sodium-glucose co-transporter-2 (SGLT2) Inhibitors
6.2. Global Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Intramuscular
6.3. Global Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Retail Pharmacy
Hospital Pharmacy
Online Pharmacy
6.4. Global Non-Insulin Therapies For Diabetes Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Monitoring
Diagnosis
Treatment
Other Applications
6.5. Global Non-Insulin Therapies For Diabetes Market, Sub-Segmentation Of Biguanides, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Metformin
Combination Of Metformin With Other Drugs
6.6. Global Non-Insulin Therapies For Diabetes Market, Sub-Segmentation Of Sulfonylureas, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Glimepiride
Glipizide
Glyburide
6.7. Global Non-Insulin Therapies For Diabetes Market, Sub-Segmentation Of Thiazolidinediones, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pioglitazone
Rosiglitazone
6.8. Global Non-Insulin Therapies For Diabetes Market, Sub-Segmentation Of Alpha-Glucosidase Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Acarbose
Miglitol
6.9. Global Non-Insulin Therapies For Diabetes Market, Sub-Segmentation Of Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Sitagliptin
Saxagliptin
Linagliptin
Alogliptin
6.10. Global Non-Insulin Therapies For Diabetes Market, Sub-Segmentation Of Glucagon-Like Peptide-1 (GLP-1) Analogs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Exenatide
Liraglutide
Dulaglutide
Semaglutide
6.11. Global Non-Insulin Therapies For Diabetes Market, Sub-Segmentation Of Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Canagliflozin
Dapagliflozin
Empagliflozin

7. Non-Insulin Therapies For Diabetes Market Regional And Country Analysis

7.1. Global Non-Insulin Therapies For Diabetes Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Non-Insulin Therapies For Diabetes Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Non-Insulin Therapies For Diabetes Market

8.1. Asia-Pacific Non-Insulin Therapies For Diabetes Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Non-Insulin Therapies For Diabetes Market

9.1. China Non-Insulin Therapies For Diabetes Market Overview
9.2. China Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Non-Insulin Therapies For Diabetes Market

10.1. India Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Non-Insulin Therapies For Diabetes Market

11.1. Japan Non-Insulin Therapies For Diabetes Market Overview
11.2. Japan Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Non-Insulin Therapies For Diabetes Market

12.1. Australia Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Non-Insulin Therapies For Diabetes Market

13.1. Indonesia Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Non-Insulin Therapies For Diabetes Market

14.1. South Korea Non-Insulin Therapies For Diabetes Market Overview
14.2. South Korea Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Non-Insulin Therapies For Diabetes Market

15.1. Western Europe Non-Insulin Therapies For Diabetes Market Overview
15.2. Western Europe Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Non-Insulin Therapies For Diabetes Market

16.1. UK Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Non-Insulin Therapies For Diabetes Market

17.1. Germany Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Non-Insulin Therapies For Diabetes Market

18.1. France Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Non-Insulin Therapies For Diabetes Market

19.1. Italy Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Non-Insulin Therapies For Diabetes Market

20.1. Spain Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Non-Insulin Therapies For Diabetes Market

21.1. Eastern Europe Non-Insulin Therapies For Diabetes Market Overview
21.2. Eastern Europe Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Non-Insulin Therapies For Diabetes Market

22.1. Russia Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Non-Insulin Therapies For Diabetes Market

23.1. North America Non-Insulin Therapies For Diabetes Market Overview
23.2. North America Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Non-Insulin Therapies For Diabetes Market

24.1. USA Non-Insulin Therapies For Diabetes Market Overview
24.2. USA Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Non-Insulin Therapies For Diabetes Market

25.1. Canada Non-Insulin Therapies For Diabetes Market Overview
25.2. Canada Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Non-Insulin Therapies For Diabetes Market

26.1. South America Non-Insulin Therapies For Diabetes Market Overview
26.2. South America Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Non-Insulin Therapies For Diabetes Market

27.1. Brazil Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Non-Insulin Therapies For Diabetes Market

28.1. Middle East Non-Insulin Therapies For Diabetes Market Overview
28.2. Middle East Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Non-Insulin Therapies For Diabetes Market

29.1. Africa Non-Insulin Therapies For Diabetes Market Overview
29.2. Africa Non-Insulin Therapies For Diabetes Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Non-Insulin Therapies For Diabetes Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Non-Insulin Therapies For Diabetes Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Non-Insulin Therapies For Diabetes Market Competitive Landscape And Company Profiles

30.1. Non-Insulin Therapies For Diabetes Market Competitive Landscape
30.2. Non-Insulin Therapies For Diabetes Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Sanofi Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. The Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

31. Non-Insulin Therapies For Diabetes Market Other Major And Innovative Companies

31.1. AstraZeneca plc
31.2. Novartis AG
31.3. GSK plc
31.4. Takeda Pharmaceutical Company Limited
31.5. Eli Lilly and Company
31.6. Novo Nordisk A/S
31.7. Boehringer Ingelheim International GmbH
31.8. Les Servier Laboratories
31.9. Sumitomo Dainippon Pharma Co. Ltd.
31.10. Jiangsu Hansoh Pharmaceutical Group Co. Ltd.
31.11. Uni-Bio Science Group Ltd.
31.12. Intarcia Therapeutics
31.13. Janssen Pharmaceuticals
31.14. Boan Biotech
31.15. SatRx LLC

32. Global Non-Insulin Therapies For Diabetes Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Non-Insulin Therapies For Diabetes Market

34. Recent Developments In The Non-Insulin Therapies For Diabetes Market

35. Non-Insulin Therapies For Diabetes Market High Potential Countries, Segments and Strategies

35.1 Non-Insulin Therapies For Diabetes Market In 2029 - Countries Offering Most New Opportunities
35.2 Non-Insulin Therapies For Diabetes Market In 2029 - Segments Offering Most New Opportunities
35.3 Non-Insulin Therapies For Diabetes Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer